Use of hypnotic drugs among children, adolescents, and young adults in Scandinavia.
Scandinavia
hypnotics
insomnia
melatonin
sleep disorders
utilization
Journal
Acta psychiatrica Scandinavica
ISSN: 1600-0447
Titre abrégé: Acta Psychiatr Scand
Pays: United States
ID NLM: 0370364
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
06
05
2021
received:
11
03
2021
accepted:
14
05
2021
pubmed:
23
5
2021
medline:
11
9
2021
entrez:
22
5
2021
Statut:
ppublish
Résumé
Hypnotic use in children and adolescents is controversial. To describe the use of hypnotic drugs (melatonin, z-drugs, and sedating antihistamines) among 5- to 24-year-old Scandinavians during 2012 to 2018. Aggregate-level data were obtained from public data sources in Sweden, Norway, and Denmark. We calculated annual prevalence (users/1000 inhabitants) stratified by age group, sex, and country. Quantity of use (Defined Daily Dose (DDD)/user/day) was estimated for Norway and Denmark. Melatonin was the most commonly used hypnotic, and its use increased markedly from 2012 to 2018, particularly among females and 15- to 24-year-old individuals. Sweden had the highest increase in use (6.5 to 25/1000) compared with Norway (10-20/1000) and Denmark (5.7-12/1000). The annual prevalence of sedating antihistamine use was also highest in Sweden, reaching 13/1000 in 2018 in comparison to 7.5/1000 in Norway and 2.5/1000 in Denmark. Z-drug use decreased in all countries toward 2018, dropping to 3.5/1000 in Sweden, 4.4/1000 in Norway, and 1.7/1000 in Denmark. The quantity of hypnotic use in Norway and Denmark was 0.8-1.0 DDD/user/day for melatonin in 2018, as compared to 0.1-0.3 for z-drugs and antihistamines. The use of melatonin and sedating antihistamines increased among young Scandinavians during 2012-2018, and the increase was twice as high in Sweden compared with Norway and Denmark. In addition, Sweden had the highest use of sedating antihistamines. The Scandinavian variation of hypnotic use could reflect differences in frequency of sleep problems between populations or variation of healthcare access or clinical practice between countries.
Sections du résumé
BACKGROUND
Hypnotic use in children and adolescents is controversial.
OBJECTIVE
To describe the use of hypnotic drugs (melatonin, z-drugs, and sedating antihistamines) among 5- to 24-year-old Scandinavians during 2012 to 2018.
METHODS
Aggregate-level data were obtained from public data sources in Sweden, Norway, and Denmark. We calculated annual prevalence (users/1000 inhabitants) stratified by age group, sex, and country. Quantity of use (Defined Daily Dose (DDD)/user/day) was estimated for Norway and Denmark.
RESULTS
Melatonin was the most commonly used hypnotic, and its use increased markedly from 2012 to 2018, particularly among females and 15- to 24-year-old individuals. Sweden had the highest increase in use (6.5 to 25/1000) compared with Norway (10-20/1000) and Denmark (5.7-12/1000). The annual prevalence of sedating antihistamine use was also highest in Sweden, reaching 13/1000 in 2018 in comparison to 7.5/1000 in Norway and 2.5/1000 in Denmark. Z-drug use decreased in all countries toward 2018, dropping to 3.5/1000 in Sweden, 4.4/1000 in Norway, and 1.7/1000 in Denmark. The quantity of hypnotic use in Norway and Denmark was 0.8-1.0 DDD/user/day for melatonin in 2018, as compared to 0.1-0.3 for z-drugs and antihistamines.
CONCLUSION
The use of melatonin and sedating antihistamines increased among young Scandinavians during 2012-2018, and the increase was twice as high in Sweden compared with Norway and Denmark. In addition, Sweden had the highest use of sedating antihistamines. The Scandinavian variation of hypnotic use could reflect differences in frequency of sleep problems between populations or variation of healthcare access or clinical practice between countries.
Substances chimiques
Hypnotics and Sedatives
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100-112Subventions
Organisme : NIMH NIH HHS
ID : R01 MH114967
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Carter JC, Wrede JE. Overview of sleep and sleep disorders in infancy and childhood. Pediatr Ann. 2017;46:e133-e138.
Olfson M, Wall M, Liu S-M, Morin CM, Blanco C. Insomnia and impaired quality of life in the United States. J Clin Psychiatry. 2018;79.
Maski K, Owens JA. Insomnia, parasomnias, and narcolepsy in children: clinical features, diagnosis, and management. Lancet Neurol. 2016;15:1170-1181.
Kocevska D, Lysen TS, Dotinga A, et al. Sleep characteristics across the lifespan in 1.1 million people from the Netherlands, United Kingdom and United States: a systematic review and meta-analysis. Nat. Hum Behav. 2021;5:113-122.
World Health Organization. ICD-10: international statistical classification of diseases and related health problems. Geneva: World Health Organization; 2004.
Meltzer LJ, Mindell JA. Systematic review and meta-analysis of behavioral interventions for pediatric insomnia. J Pediatr Psychol. 2014;39:932-948.
Zetterqvist V, Lundén C, Herrmann A, et al. Internet-delivered cognitive behaviour therapy for adolescents with insomnia comorbid to psychiatric conditions: A non-randomised trial. Clin Child Psychol Psychiatry. 2021;26(2):475-489.
Åslund L, Lekander M, Wicksell RK, Henje E, Jernelöv S. Cognitive-behavioral therapy for insomnia in adolescents with comorbid psychiatric disorders: A clinical pilot study. Clin Child Psychol Psychiatry. 2020;25:958-971.
Bruni O, Angriman M, Calisti F, et al. Practitioner Review: Treatment of chronic insomnia in children and adolescents with neurodevelopmental disabilities. J Child Psychol Psychiatry. 2018;59:489-508.
Parker A, Beresford B, Dawson V, et al. Oral melatonin for non-respiratory sleep disturbance in children with neurodisabilities: systematic review and meta-analyses. Dev Med Child Neurol. 2019;61:880-890.
Abdelgadir IS, Gordon MA, Akobeng AK. Melatonin for the management of sleep problems in children with neurodevelopmental disorders: a systematic review and meta-analysis. Arch Dis Child. 2018;103:1155-1162.
Wei S, Smits MG, Tang X, et al. Efficacy and safety of melatonin for sleep onset insomnia in children and adolescents: a meta-analysis of randomized controlled trials. Sleep Med. 2020;68:1-8.
U.S. FOOD & DRUG ADMINISTRATION. FDA adds Boxed Warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medicines; 2019. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-prescription-insomnia: www.fda.gov [updated 2019; cited].
McCall WV, Benca RM, Rosenquist PB, et al. Hypnotic medications and suicide: risk, mechanisms, mitigation, and the FDA. Am J Psychiatry. 2017;174:18-25.
EUROPEAN MEDICINES AGENCY. Slenyto (melatonin); 2018. Available from: https://www.ema.europa.eu/en/documents/overview/slenyto-epar-medicine-overview_en.pdf [updated 2018; cited]; EMA/570422/2018 EMEA/H/C/004425.
Alonso-Alconada D, Alvarez A, Arteaga O, Martinez-Ibarguen A, Hilario E. Neuroprotective effect of melatonin: a novel therapy against perinatal hypoxia-ischemia. Int J Mol Sci. 2013;14:9379-9395.
Tan DX, Manchester LC, Terron MP, Flores LJ, Reiter RJ. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res. 2007;42:28-42.
Brzezinski A. Melatonin in humans. N Engl J Med. 1997;336:186-195.
Braam W, Smits MG, Didden R, Korzilius H, Geijlswijk IMV, Curfs LMG. Exogenous melatonin for sleep problems in individuals with intellectual disability: a meta-analysis. Dev Med Child Neurol. 2009;51:340-349.
Crowley SJ, Acebo C, Carskadon MA. Human puberty: salivary melatonin profiles in constant conditions. Dev Psychobiol. 2012;54:468-473.
EUROPEAN MEDICINES AGENCY. PART VI SUMMARY OF THE RISK MANAGEMENT PLAN. Active substance(s): Melatonin; 2018. Available from: https://www.ema.europa.eu/en/documents/rmp-summary/slenyto-epar-risk-management-plan-summary_en.pdf [updated 2018; cited].
Furster C, Hallerbäck MU. The use of melatonin in Swedish children and adolescents-a register-based study according to age, gender, and medication of ADHD. Eur J Clin Pharmacol. 2015;71:877-881.
Hartz I, Handal M, Tverdal A, Skurtveit S. Paediatric off-label use of melatonin-a register linkage study between the Norwegian prescription database and patient register. Basic Clin Pharmacol Toxicol. 2015;117:267-273.
Schmidt M, Hallas J, Laursen M, Friis S. Data Resource Profile: Danish online drug use statistics (MEDSTAT). Int J Epidemiol. 2016;45:1401-1402.
Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, SÃrensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol. 2010;106:86-94.
World Health Organization. Guidelines for ATC classification and DDD assignment 2019. WHO Collaborating Centre for Drug Statistics Methodology; 2018.
R Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2018.
Tidyverse WH. Tidyverse: Easily Install and Load the ‘Tidyverse’, R Package version 1.2.1.; 2017.
WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index; 2020. Available from: https://www.whocc.no/atc_ddd_index/?code=N05CH01 [updated 2020; cited].
Swedish Medical Products Agency (Läkemedelsverket). Behandling av sömnstörningar hos barn och ungdomar - kunskapsdokument; 2014. Available from: https://www.lakemedelsverket.se/sv/behandling-och-forskrivning/behandlingsrekommendationer/sok-behandlingsrekommendationer/behandling-av-somnstorningar-hos-barn-och-ungdomar--kunskapsdokument#hmainbody1 [updated 2014; cited].
The Norwegian Medical Association (DEN NORSKE LEGEFORENING). Veileder i BUP 4. utgave, Faglig veileder for barne- og ungdomspsykiatri; 2019. Available from: https://www.legeforeningen.no/contentassets/308e31a34fb84ab59b7fe2cd0159c476/bup-med-innholdsfortegnelse-nt010719.pdf [updated 2019; cited].
DANISH MEDICINES AGENCY (LAEGEMIDDELSTYRELSEN). Melatonin, Brugere mellem 0-17 år af laegemidler med melatonin; 2016. Available from: https://laegemiddelstyrelsen.dk/da/udgivelser/2016/melatonin-brugere-mellem-0-17-aar-af-laegemidler-med-melatonin/~/media/A79D51A9E9C445CA9D2FFE8C23B14396.ashx [updated 2016; cited].
DANISH HEALTH AUTHORITY (SUNDHEDSSTYRELSEN). Vejledning om medikamentel behandling hos børn og unge med psykiske lidelser; 2013 Contract No.: Document Number|.
Steinhausen H-C. Recent international trends in psychotropic medication prescriptions for children and adolescents. Eur Child Adolesc Psychiatry. 2015;24:635-640.
Bachmann CJ, Wijlaars LP, Kalverdijk LJ, et al. Trends in ADHD medication use in children and adolescents in five western countries, 2005-2012. Eur Neuropsychopharmacol. 2017;27:484-493.
Pottegård A, Bjerregaard BK, Glintborg D, Hallas J, Moreno SI. The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective. Eur J Clin Pharmacol. 2012;68:1443-1450.
Furu K, Karlstad Ø, Zoega H, et al. Utilization of stimulants and atomoxetine for attention-deficit/hyperactivity disorder among 5.4 million children using population-based longitudinal data. Basic Clin Pharmacol Toxicol. 2017;120:373-379.
Steffenak AK, Wilde-Larsson B, Nordström G, Skurtveit S, Hartz I. Increase in psychotropic drug use between 2006 and 2010 among adolescents in Norway: a nationwide prescription database study. Clin Epidemiol. 2012;4:225-231.
Nielsen ES, Hellfritzsch M, Sorensen MJ, Rasmussen H, Thomsen PH, Laursen T. Off-label prescribing of psychotropic drugs in a Danish child and adolescent psychiatric outpatient clinic. Eur Child Adolesc Psychiatry. 2016;25:25-31.
Hysing M, Pallesen S, Stormark KM, Jakobsen R, Lundervold AJ, Sivertsen B. Sleep and use of electronic devices in adolescence: results from a large population-based study. BMJ Open. 2015;5(1):e006748.
Ghekiere A, Van Cauwenberg J, Vandendriessche A, et al. Trends in sleeping difficulties among European adolescents: Are these associated with physical inactivity and excessive screen time? Int J Public Health. 2019;64:487-498.
Carter B, Rees P, Hale L, Bhattacharjee D, Paradkar MS. Association between portable screen-based media device access or use and sleep outcomes. A systematic review and meta-analysis. JAMA Pediatr. 2016;170:1202-1208.
Sohn SY, Rees P, Wildridge B, Kalk NJ, Carter B. Prevalence of problematic smartphone usage and associated mental health outcomes amongst children and young people: a systematic review, meta-analysis and GRADE of the evidence. BMC Psychiatry. 2019;19(1):356.
Thorsteinsson EB, Potrebny T, Arnarsson ÁM, Tynjälä J, Välimaa R, Eriksson C. Trends in sleeping difficulty among adolescents in five Nordic countries 2002-2014. Nordisk välfärdsforskning| Nordic Welfare. Research. 2018;4:77-87.
Cosma A, Stevens G, Martin G, et al. Cross-national time trends in adolescent mental well-being from 2002 to 2018 and the explanatory role of schoolwork pressure. J Adolesc Health. 2020;66:S50-S58.
PUBLIC HEALTH AGENCY OF SWEDEN (FOLKHÄLSOMYNDIGHETEN). Varför har den psykiska ohälsan ökat bland barn och unga i Sverige? Utvecklingen under perioden 1985−2014; 2018. Available from: https://www.folkhalsomyndigheten.se/contentassets/628f1bfc932b474f9503cc6f8e29fd45/varfor-psykiska-ohalsan-okat-barn-unga-18023-2-webb-rapport.pdf [updated 2018].
Schifano F, Chiappini S, Corkery JM, Guirguis A. An insight into Z-drug abuse and dependence: an examination of reports to the european medicines agency database of suspected adverse drug reactions. Int J Neuropsychopharmacol. 2019;22:270-277.
Hvolby A, Christensen J, Gasse C, Dalsgaard S, Dreier JW. Cumulative incidence and relative risk of sleep problems among children and adolescents with newly diagnosed neurodevelopmental disorders: A nationwide register-based study. J Sleep Res. 2021;30:e13122.
Bachmann CJ, Aagaard L, Burcu M, et al. Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005-2012. Eur Neuropsychopharmacol. 2016;26:411-419.
Steinhausen HC, Bisgaard C. Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark. Acta Psychiatr Scand. 2014;129:221-231.
Jeppesen P, Obel C, Lund L, Madsen KB, Nielsen L Mental sundhed og sygdom hos børn og unge i alderen 10-24 år - forekomst, udvikling og forebyggelsesmuligheder. Vidensråd For Forebyggelse 2020.
Dalsgaard S, Thorsteinsson E, Trabjerg BB, et al. Incidence rates and cumulative incidences of the full spectrum of diagnosed mental disorders in childhood and adolescence. JAMA Psychiatry. 2020;77(2):155.
Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res. 2017;26:675-700.
Wesselhoeft R, Jensen PB, Talati A, et al. Trends in antidepressant use among children and adolescents: A Scandinavian drug utilization study. Acta Psychiatr Scand. 2020;141(1):34-42.
SWEDISH MEDICAL PRODUCTS AGENCY (LÄKEMEDELSVERKET). Melatonin AGB; 2019. Available from: https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20170420000066 [updated 2019; cited].
SWEDISH MEDICAL PRODUCTS AGENCY (LÄKEMEDELSVERKET). Produktresumé Lergigan; 1953. Available from: https://docetp.mpa.se/LMF/Lergigan%20mite,%20forte,%20film-coated%20tablet%20SmPC_09001bee807a4e22.pdf: www.lakemedelsverket.se [updated 1953; cited].
SWEDISH MEDICAL PRODUCTS AGENCY (LÄKEMEDELSVERKET). Summary Public Assessment Report Prometazin Actavis; 2016. Available from: https://docetp.mpa.se/LMF/Prometazin%20Actavis%20film-coated%20tablet%20ENG%20PAR_09001bee807a7965.pdf: www.lakemedelsverket.se [updated 2016; cited].
Signorini G, Singh SP, Boricevic-Marsanic V, et al. Architecture and functioning of child and adolescent mental health services: a 28-country survey in Europe. Lancet Psychiatry. 2017;4:715-724.
Pottegård A, Christensen RD, Houji A, et al. Primary non-adherence in general practice: a Danish register study. Eur J Clin Pharmacol. 2014;70:757-763.